What question did this study set out to answer?

To evaluate available safety and efficacy data to determine recommendations for the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years.

May 14, 2021MMWR Morbidity and Mortality Weekly ReportOpen Access

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

View Full Paper

Ask AI

Bookmark

Authors

MWMegan WallaceLouisiana State Department of Health and Hospitals KWKate R. WoodworthNational Center on Birth Defects and Developmental Disabilities JGJulia W. GarganoCenters for Disease Control and Prevention

Discussion

Member takes

Implication

Systematic review demonstrates favorable evidence for Pfizer-BioNTech vaccination in adolescents aged 12–15 years, supporting expanded COVID-19 prevention guidelines.

Key Points

To evaluate available safety and efficacy data to determine recommendations for the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years.
Conducted a systematic review of all available clinical trial and safety data regarding COVID-19 vaccination in adolescents aged 12–15 years.
Deliberated within the Advisory Committee on Immunization Practices to formulate national public health interim guidance.
The Advisory Committee on Immunization Practices issued an interim recommendation supporting the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years.
Available evidence supported the vaccine's role in preventing COVID-19 infection in the adolescent population.

Cite This Study

Wallace et al. (2021) studied this question.

synapsesocial.com/papers/6a9942a02beb1e1a0778e2a2 https://doi.org/10.15585/mmwr.mm7020e1

View Full Paper

Ask AI

Bookmark

Implication

Systematic review demonstrates favorable evidence for Pfizer-BioNTech vaccination in adolescents aged 12–15 years, supporting expanded COVID-19 prevention guidelines.

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

Discussion

Member takes

Implication

Key Points

Cite This Study

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider